Antimicrobial Susceptibility StudiesThe changing epidemiology of Acinetobacter spp. producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report
Section snippets
Conflict of interests
A.C.G. has recently received research funding and/or consultation fees from AstraZeneca, MSD, and Novartis. A.S.L. provided consultation to Eurofarma. B.R.L. was a speaker for GSK and Pfizer. The other authors have nothing to declare.
Funding
This study was partially supported by a grant of Institut Mérieux. A.T.R.V. received a Mérieux Research Grants 2013 (Network–Brazil: Identification and characterization of bacterial pathogens in nosocomial infection management).
References (22)
- et al.
Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008-2011): countrywide spread of OXA-23-producing clones (CC15 and CC79)
Diagn Microbiol Infect Dis
(2014) - et al.
Emergence of extensively drug-resistant OXA-72-producing Acinetobacter baumannii in Recife, Brazil: risk of clonal dissemination?
Diagn Microbiol Infect Dis
(2013) - et al.
Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS
Clin Microbiol Infect
(2012) - et al.
Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010)
Diagn Microbiol Infect Dis
(2012) - et al.
Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp
Int J Antimicrob Agents
(2010) - et al.
High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil
Int J Antimicrob Agents
(2012) - et al.
Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005–2009)
Clin Microbiol Infect
(2013) - et al.
Acinetobacter baumannii extensively drug resistant lineages in Buenos Aires hospitals differ from the international clones I-III
Infect Genet Evol
(2013) Acinetobacter: an old friend, but a new enemy
J Hosp Infect
(2009)- et al.
High prevalence of carbapenem-resistant Acinetobacter baumannii carrying the blaOXA-143 gene in Brazilian hospitals
Antimicrob Agents Chemother
(2011)
Boletim Informativo: Segurança e qualidade em serviço de saúde n° 9: Relatório da resistência microbiana em infecções primárias de corrente sanguínea confirmadas laboratorialmente relacionadas ao uso de cateter venoso central em unidades de terapia intensiva
Cited by (43)
Genomic analysis of Klebsiella pneumoniae high-risk clone ST11 co-harbouring MCR-1.27 and KPC-2 recovered at a paediatric oncologic hospital in the Brazilian Amazon region
2023, Journal of Global Antimicrobial ResistanceGenomic and phenotypic characterisation of antimicrobial resistance in carbapenem-resistant Acinetobacter baumannii hyperendemic clones CC1, CC15, CC79 and CC25
2020, International Journal of Antimicrobial AgentsHealthcare-associated carbapenem-resistant OXA-72-producing Acinetobacter baumannii of the clonal complex CC79 colonizing migratory and captive aquatic birds in a Brazilian Zoo
2020, Science of the Total EnvironmentCitation Excerpt :The production of OXA-type carbapenemases has been the main mechanism of carbapenem resistance in Acinetobacter baumannii. In Brazil, whereas OXA-23 and OXA-143 CHDLs have been prevalent, OXA-72 (enzyme belonged to OXA-24/40 group) has begun to be increasingly reported also (Vasconcelos et al., 2015; Pagano et al., 2017). Molecular epidemiological studies on carbapenem-resistant A. baumannii have highlighted the worldwide dissemination of the international clone 1 (Clonal Complex, CC1), whereas international clones 2 (CC2) and 3 (CC3) have been prevalent in Europe and the United States of America (Zarrilli et al., 2013).
Molecular epidemiology of carbapenem-resistant isolates of Acinetobacter baumannii in Argentina
2019, Revista Argentina de MicrobiologiaTemporal evolution of Acinetobacter baumannii ST107 clone: conversion of bla <inf>OXA-143</inf> into bla <inf>OXA-231</inf> coupled with mobilization of ISAba1 upstream occAB1
2019, Research in MicrobiologyCitation Excerpt :Although carbapenems have long been considered the first choice treatment for A. baumannii infections, nosocomial outbreaks caused by carbapenem-resistant clones are now frequently reported [1,5,6]. The production of carbapenem-hydrolyzing class D β-lactamases (CHDLs) has been the main mechanism associated with carbapenem resistance in this pathogen [4–6]. In Brazil, during the past decade, high carbapenem resistance rates were observed in A. baumannii according to the last bulletin of Brazilian Health Surveillance Agency (ANVISA) of 2017, being mainly associated with the spread of clones carrying blaOXA-23 [5,6].
Carbapenemases in Acinetobacter baumannii. Review of their dissemination in Latin America
2018, Revista Argentina de MicrobiologiaCitation Excerpt :The worldwide dissemination of blaOXA-23 would be related to International clones I or II. In South America (SA) this carbapenemase has been commonly associated with CC113/CC79; however, it has also been detected in clones recovered in a lower proportion (CC104/CC15, CC110/ST25, CC109/CC1) and in many sporadic isolates3,6,9,14–17,28–30,34,36. Some OXA-23 allelic variants, such as OXA-239, have been described, which showed a major presence in studies conducted in the south of Mexico in the year 20141.